%0 Journal Article
%T Treatment Satisfaction and Acceptability of 20% Aminolevulinic Acid Photodynamic Therapy for the Treatment of Actinic Keratoses of the Face, Scalp, and Upper Extremities.
%A Piacquadio D
%A Berman B
%A Siegel DM
%A Bhatia N
%A Brocato J
%A Squittieri N
%A Pariser DM
%J J Clin Aesthet Dermatol
%V 16
%N 12
%D 2023 Dec
%M 38125671
暂无%X <B>UNASSIGNED: </B>Actinic keratoses (AKs) are precancerous, dysplastic, epidermal lesions caused by chronic sun exposure that may progress to squamous cell carcinoma. Aminolevulinic acid 20% solution with blue light photodynamic therapy (ALA-PDT) has previously been shown to be superior to vehicle plus PDT (VEH-PDT) for treatment of AKs of the face, scalp, and upper extremities.<BR><B>UNASSIGNED: </B>We report detailed patient satisfaction data for ALA-PDT.<BR><B>UNASSIGNED: </B>Patient satisfaction for ALA-PDT versus VEH-PDT and patient-reported acceptability of ALA-PDT versus previous treatments for AKs were assessed in three randomized, vehicle-controlled studies (two Phase II and one Phase III) in adults. Patients in the Phase II studies were treated on the scalp and/or face, and those in the Phase III study were treated on the upper extremities.<BR><B>UNASSIGNED: </B>A total of 234, 166, and 269 patients were enrolled in the two Phase II studies and one Phase III study, respectively; overall, 79.8 percent of patients were male. Overall treatment satisfaction ranged from 79 to 88 percent for ALA-PDT, compared to 35 to 56 percent for VEH-PDT. Patients generally considered ALA-PDT to be equivalent to or more acceptable than prior treatments, including cryotherapy, 5-fluorouracil, imiquimod, previous PDT, and surgery. Similar proportions of patients receiving ALA-PDT or VEH-PDT on the upper extremities considered in-office time, side effects/adverse events (AEs), and duration of side effects/AEs to be acceptable.<BR><B>UNASSIGNED: </B>The majority of patients were male, and no statistical comparisons were conducted.<BR><B>UNASSIGNED: </B>Patients were generally satisfied with ALA-PDT for the treatment of AKs of the face, scalp, and upper extremities and considered ALA-PDT to be equal to or more acceptable than previous treatments.<BR><B>UNASSIGNED: </B>ClinicalTrials.gov: NCT01475955; NCT02239679; NCT02137785.